Asoprisnil (INN; developmental code name J-867) is a synthetic, steroidal selective progesterone receptor modulator that was under development by Schering and TAP Pharmaceutical Products for the treatment of uterine fibroids.

[1] In 2005, phase III clinical trials were discontinued due to endometrial changes in patients.

[2]

This antineoplastic or immunomodulatory drug article is a stub.

You can help Wikipedia by expanding it.